Peptide Research News - GSK announces new 52-week data from phase III study of once-weekly albiglutide ... - PipelineReview.com (press release)

GSK announces new 52-week data from phase III study of once-weekly albiglutide ... - PipelineReview.com (press release)

GSK announces new 52-week data from phase III study of once-weekly albiglutide ... PipelineReview.com (press release) LONDON, UK I June 9, 2012 I Detailed findings from a Phase III study comparing the investigational glucagon-like peptide-1 (GLP-1) receptor agonist albiglutide to prandial insulin (Lispro), were presented today at the American Diabetes Association ... GSK Report Data From PhaseIII Study Of Once-weekly Albiglutide In Type2 DiabetesNASDAQ all 5 news articles »

Click Here to read the entire article...